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Report on three consecutive randomized phase II trials using 
single-agent docetaxel and gemcitabine in diferent doses and 
schedules for patients in advanced non-small cell lung cancer 
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Background: Platinum based doublet chemotherapy is considered 
standard but is often clinical inappropriate. Newer drugs as docetaxel 
and gemcitabine given as single agents in 1st- and 2nd-line have shown 
favorable toxicity and signiﬁcant efﬁcacy. It is assumed that sequencing 
of docetaxel and gemcitabine could be an equally effective alternative 
for palliation. Treatment: From 1998 to 2004 a total of 819 patients 
have been included in three studies (Figure): two to identify an optimal 
single agent sequence; and one to compare sequential single agents to a 
platinum-free doublet. 
Figure: Treatment in the three consecutive studies GemTax I-III
Common eligibility criteria were employed, including histologically 
conﬁrmed stage “wet IIIB” or IV, performance status (PS) 0-2, and no 
prior chemotherapy. The ﬁrst two studies were to decide whether gem-
citabine or docetaxel, switching to the opposite drug in case of disease 
progression, is feasible. Treatment feasibility was deﬁned as the pa-
tients’ ability to receive ≥2 cycles of 1st-line and in case of progression 
≥2 cycles of 2nd-line therapy and to survive at least 7 months. Primary 
endpoint of the third study was clinically relevant haemato-toxicity 
deﬁned as thrombocytopenia requiring platelet transfusions, anaemia 
with RBC-transfusions or febrile neutropenia with i.v. antibiotics. 
Results: 85% of patients had stage IV disease and 85% PS≤1. Treat-
ment feasibility as deﬁned for the ﬁrst study was 28% (GeméDoc) and 
20% (DocéGem) (not signiﬁcant). Median survival was 9.0/5.0 months 
(p=.03), and median time to progression was 4.3/2.2 months. Treat-
ment feasibility as deﬁned for the second study was 38% (GeméDoc) 
and 49% (DocéGem) (p=.04). Median survival was 6.3/8.6 months, 
and median time to progression was 2.4/3.3 months. In the third study 
clinically relevant haemato-toxicity occurred less frequently under 
single agent therapy (p<.001) and transfusions and i.v. antibiotics treat-
ment days again were less common. The quality of life assessment also 
favored single agent therapy. Median survival was 7.3 (Gem+Doc)/
7.4(GeméDoc) months, response rate was 33%/22% (p=.05) and 
median time to progression was 6.3/4.9 months (p=.04). 
Conclusion: The 3 studies showed that sequencing modern single 
agent can be effective and is well tolerated. Using docetaxel and gem-
citabine as weekly regimens seem to be less feasible than the 3-weekly 
regimens. The use of the single agents is associated with reduced 
clinically relevant haemato-toxicity, less i.v. antibiotics, a better quality 
of life, and is furthermore more cost-effective if compared to the non-
platinum doublet.
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Between 2002 and 2005, 75 pts with locally advanced or recurrent or 
metastatic NSCLC were treated with Carboplatin/Gemzar protocol 
(Carboplatin - AUC -5 day 1 Gemzar-1000 mg/m2 days 1 and 8 in 3 
weeks cycle).
Their median age was- 67 years (range 36.2- 84.1).
50 pts in age younger than 75 years (range 36.2- 74.7 years; median 
age- 67 years) - and 25 patients were 75 or older (range 75- 84.1; 
median age 77.6 years). The two age groups were compared for clinical 
features and treatment feasibility and outcome.
PS was 0- 1 in 72% of younger patients and in 68% of the older group . 
Treatment intent was neo-adjuvant in 12% of pts; and palliative in 88% 
of younger patients and 8% and 92% respectively of the older group.
The younger patients received a median of 5 cycles of therapy (range 
1-15) with a mean dose density 85%. The older group received median 
- 4 therapy cycles (range 1-8). With a mean dose density -72%. Grade 
III- IV myelotoxicity was observed in 53.2% of younger and 40% 
in older patients. Grade III- IV non hematological toxicity (mainly 
fatigue) was observed in 8.3 % younger patients and 17.4% of older 
patients respectively. Quality of life was considered by patients as 
improved with treatment in 15.6% of the younger patients and in 20.8% 
of older patients. Worse quality of life was reported during therapy by 
55.6% of younger and 71% of older group respectively. 
In the younger group PR was achieved in 25.5% of patients; MR or SD 
in 19.2%, TP in 34% and 21.3 % were not evaluable for response. In 
the older population PR was achieved 37.5%; MR or SD- 29.2 %; TP 
- 16.7% and 16.7 % were not evaluable.
Second line chemotherapy was administered to 64.6% of younger 
patients but only 32% of the older ones. With the median follow up of 
11 months (range 0.9- 41.6 months) 66% of younger and 72% older 
patients died of their disease.
Conclusion: Carboplatin/Gemzar combination was used less aggres-
sively in the older population and still seems more toxic in this popula-
tion. The more striking difference was the worsening of quality of life 
in the older group. Although the therapeutic effect was comparable; 
a less toxic regimen should be considered in the palliative therapy of 
older patients with advanced or metastatic NSCLC. 
